Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 12, 2018. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. It does not contain financial performance results, operational updates, or strategic commentary.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of specific share transactions and does not report on the company's financial position.
Material Changes and Transaction Details
The filing details acquisitions of GSK Ordinary Shares (ISIN: GB0009252882) by nine senior executives under the Company's Share Reward Plan. All transactions occurred on December 11, 2018, on the London Stock Exchange (XLON) at a price of £14.9439 per share.
- Ms E Walmsley (Chief Executive Officer): Acquired 16 shares (8 partnership, 8 matching).
- Mr R G Connor (President, Global Vaccines): Acquired 16 shares (8 partnership, 8 matching).
- Mr S Dingemans (Chief Financial Officer): Acquired 16 shares (8 partnership, 8 matching).
- Mr N Hirons (SVP, Global Ethics & Compliance): Acquired 16 shares (8 partnership, 8 matching).
- Mr L Miels (President, Global Pharmaceuticals): Acquired 16 shares (8 partnership, 8 matching).
- Mr D S Redfern (Chief Strategy Officer): Acquired 16 shares (8 partnership, 8 matching).
- Mr R Simard (President, Pharma Supply Chain): Acquired 18 shares (9 partnership, 9 matching).
- Ms C Thomas (SVP, Human Resources): Acquired 16 shares (8 partnership, 8 matching).
- Mr P C Thomson (President, Global Affairs): Acquired 16 shares (8 partnership, 8 matching).
- Mrs V A Whyte (Company Secretary): Acquired 16 shares (8 partnership, 8 matching).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the statutory reporting of the aforementioned share acquisitions.
Investor Verification Checklist
- Verify the total number of shares acquired by PDMRs (162 shares total) against the company's broader share buyback or compensation programs.
- Confirm the transaction price of £14.9439 aligns with the market price on December 11, 2018.
- Note that this filing contains no financial performance data; refer to the most recent Form 20-F or quarterly reports for revenue and earnings metrics.
- Review the "Share Reward Plan" terms to understand the vesting conditions for the partnership and matching shares acquired.